Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Thoracic 1Sarcoma 1NET 1Lymphoid 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 6Colorectal Neoplasms 5Neoplasm Metastasis 4Sarcoma 2Rectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Ovarian Neoplasms 1Neoplasms 1Lymphoma 1Jaundice 1Insulin-Like Growth Factor I, Resistance To 1Gastrointestinal Neoplasms 1Endocrine Gland Neoplasms 1Carcinoid Tumor 1

Interventions

lanreotide 2Temozolomide 2Capecitabine 2zimberelimab 1veliparib 1pembrolizumab 1ganitumab 1conatumumab 1arginyllysine 1Sunitinib 1Rose Bengal 1Quality of Life 1Patient Reported Outcome Measures 1Octreotide 1Molecular Diagnostic Techniques 1Immunotherapy 1Everolimus 1Drug Therapy 1Biological Therapy 1Bevacizumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × ganitumab × Gastrointestinal × Clear all
NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed
12 enrolled 21 charts
EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡